Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA4 | P51532 | 7/20 | 0.67 |
| ▸ | PBRM1 | Q86U86 | 6/20 | 0.65 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22794550 | 0.81 | SMARCA4 (1.00) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL22794557 | 0.80 | SMARCA4 (1.00) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL22794560 | 0.79 | SMARCA4 (1.00) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL22794558 | 0.78 | SMARCA4 (1.00) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL22794536 | 0.78 | SMARCA4 (1.00) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL22794544 | 0.76 | SMARCA4 (0.81) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL22794541 | 0.71 | SMARCA4 (1.00) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL21993284 | 0.70 | SMARCA4 (0.61) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL24743546 | 0.69 | PBRM1 (1.00) | SMARCA4PBRM1SMARCA2 | |
| SCHEMBL22794542 | 0.69 | SMARCA4 (0.76) | SMARCA4PBRM1SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2020251969-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | SMARCA4 5/4885PBRM1 11/4885SMARCA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.